Jonathan Glazer Shaw, MD
Family Medicine · Portland
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 18
- 6 carriers
- Office
- 1
Offices
1 location
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
18 plans · 6 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Shaw’s office at (503) 988-5558 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
18 of 18 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
| AARP Medicare Advantage from UHC CA-10 (HMO-POS) | UnitedHealthcare | Listed, may be out of date | Jun 10, 2026 |
California Medical Board record
Licence A115912 · Current
Licensed to practise in California · since 2011 · expires 2026-11-30 · Harvard Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Family Medicine - Family Medicine
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Medicaid work
$176,195 in 2024
Medicaid paid $176,195 for 2,977 billed services this clinician did in 2024, up to 62 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 425 | $162,280 |
| Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use | 92 | $6,409 |
| Screening for depression is documented as negative, a follow-up plan is not required | 198 | $2,153 |
| Alcohol and/or drug screening | 154 | $1,567 |
| Short return visit (20+ min) | 554 | $1,457 |
| Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use | 56 | $1,014 |
| Return visit (30+ min) | 144 | $811 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 343 | $355 |
| Handling and/or conveyance of specimen for transfer from physician office to laboratory | 210 | $58 |
| Short return visit | 17 | $52 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure) | 28 | $40 |
| BODY MASS INDEX DOCD | 262 | $0 |
| 2024 | 2,977 | 16 | 62 | $176,195 |
| 2023 | 2,885 | 15 | 46 | $183,266 |
| 2022 | 3,227 | 15 | 64 | $167,849 |
| 2021 | 3,536 | 14 | 76 | $255,552 |
| 2020 | 1,742 | 11 | 55 | $177,437 |
| 2019 | 1,739 | 8 | 75 | $184,798 |
| 2018 | 1,834 | 8 | 76 | $261,564 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 485 | $180,876 |
| Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use | 16 | $921 |
| Short return visit (20+ min) | 554 | $554 |
| Alcohol and/or drug screening | 20 | $192 |
| Return visit (30+ min) | 243 | $185 |
| Screening for depression is documented as negative, a follow-up plan is not required | 21 | $171 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 349 | $148 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use | 17 | $117 |
| Short return visit | 70 | $63 |
| Handling and/or conveyance of specimen for transfer from physician office to laboratory | 208 | $40 |
| BODY MASS INDEX DOCD | 315 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 271 | $0 |
2022
| Clinic visit/encounter, all-inclusive | 450 | $162,120 |
| Alcohol and/or drug screening | 239 | $1,968 |
| Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use | 51 | $1,400 |
| Screening for depression is documented as negative, a follow-up plan is not required | 224 | $1,034 |
| Short return visit (20+ min) | 515 | $516 |
| Return visit (30+ min) | 185 | $410 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 277 | $219 |
| Handling and/or conveyance of specimen for transfer from physician office to laboratory | 321 | $115 |
| Short return visit | 61 | $67 |
| BODY MASS INDEX DOCD | 210 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 222 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 211 | $0 |
2021
| Clinic visit/encounter, all-inclusive | 715 | $253,207 |
| Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use | 37 | $752 |
| Screening for depression is documented as negative, a follow-up plan is not required | 138 | $487 |
| Alcohol and/or drug screening | 107 | $480 |
| Short return visit (20+ min) | 635 | $418 |
| Return visit (30+ min) | 291 | $92 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 219 | $78 |
| Handling and/or conveyance of specimen for transfer from physician office to laboratory | 376 | $35 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure) | 43 | $3 |
| BODY MASS INDEX DOCD | 437 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 157 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 136 | $0 |
2020
| Clinic visit/encounter, all-inclusive | 495 | $173,762 |
| Return visit (30+ min) | 384 | $2,082 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use | 107 | $747 |
| Short return visit (20+ min) | 269 | $720 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 14 | $99 |
| Handling and/or conveyance of specimen for transfer from physician office to laboratory | 203 | $27 |
| BODY MASS INDEX DOCD | 69 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 27 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 13 | $0 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 101 | $0 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 60 | $0 |
2019
| Clinic visit/encounter, all-inclusive | 568 | $181,182 |
| Return visit (30+ min) | 230 | $1,879 |
| Short return visit (20+ min) | 301 | $1,396 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 25 | $186 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use | 22 | $98 |
| Handling and/or conveyance of specimen for transfer from physician office to laboratory | 316 | $58 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 259 | $0 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 18 | $0 |
2018
| Clinic visit/encounter, all-inclusive | 801 | $254,817 |
| Return visit (30+ min) | 196 | $3,487 |
| Short return visit (20+ min) | 313 | $2,255 |
| Screening for depression is documented as negative, a follow-up plan is not required | 27 | $750 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 13 | $108 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use | 12 | $81 |
| Handling and/or conveyance of specimen for transfer from physician office to laboratory | 254 | $66 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 218 | $0 |
Drugs they prescribed that Part D paid
$149,452
Pharmacies billed $149,452 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 3% of their Part D prescriptions (27 of 984) in 2024. Above the middle of the specialty; the typical family practice clinician is at 2%.
818 generic and 153 brand-name prescriptions · $149,452 in drug cost · 16 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Trulicity | 20 | $33,898 | $1,695 |
| Januvia | 17 | $23,565 | $1,386 |
| Jardiance | 16 | $22,825 | $1,427 |
| Basaglar Kwikpen U-100 | 12 | $5,586 | $466 |
| Insulin Aspart Flexpen | 12 | $1,643 | $137 |
See all 32 drugs
| Trulicity | 20 | $33,898 | $1,695 |
| Januvia | 17 | $23,565 | $1,386 |
| Jardiance | 16 | $22,825 | $1,427 |
| Basaglar Kwikpen U-100 | 12 | $5,586 | $466 |
| Insulin Aspart Flexpen | 12 | $1,643 | $137 |
| Atorvastatin | 67 | $1,452 | $22 |
| Gabapentin | 38 | $973 | $26 |
| Albuterol Sulfate Hfa | 16 | $920 | $57 |
| Omeprazole | 36 | $919 | $26 |
| Metformin | 52 | $827 | $16 |
| Diclofenac | 16 | $444 | $28 |
| Pantoprazole | 11 | $371 | $34 |
| Rosuvastatin | 13 | $356 | $27 |
| Lisinopril-Hydrochlorothiazide | 14 | $331 | $24 |
| Tamsulosin | 11 | $294 | $27 |
| Trazodone | 20 | $285 | $14 |
| Lovastatin | 12 | $277 | $23 |
| Lisinopril | 40 | $274 | $7 |
| Metoprolol | 11 | $262 | $24 |
| Fluticasone Propionate | 31 | $243 | $8 |
| Atenolol | 11 | $190 | $17 |
| Alendronate | 12 | $181 | $15 |
| Levothyroxine | 16 | $160 | $10 |
| Amlodipine Besylate | 27 | $157 | $6 |
| Losartan | 26 | $155 | $6 |
| Hydrocodone-Acetaminophen | 14 | $143 | $10 |
| Glipizide | 11 | $107 | $10 |
| Hydroxyzine | 17 | $106 | $6 |
| Chlorthalidone | 12 | $89 | $7 |
| Cyclobenzaprine | 13 | $49 | $4 |
| Hydrochlorothiazide | 24 | $36 | $2 |
| Simvastatin | 15 | $24 | $2 |
Year by year
| 2024 | 984 | 74 | 3% (27) | 16% | $149,452 |
| 2023 | 1,050 | 74 | 3% (29) | 16% | $160,114 |
| 2022 | 1,003 | 84 | 3% (32) | 14% | $128,621 |
| 2021 | 1,122 | 79 | 4% (43) | 14% | $114,805 |
| 2020 | 840 | 63 | 3% (23) | 18% | $107,176 |
| 2019 | 825 | 76 | 3% (24) | 19% | $88,228 |
| 2018 | 736 | 66 | 2% (15) | 19% | $65,360 |
| 2017 | 593 | 59 | 3% (19) | 16% | $36,998 |
| 2016 | 514 | 55 | 4% (19) | None | $35,398 |
| 2015 | 429 | 43 | 6% (27) | None | $24,409 |
| 2014 | 117 | 25 | None | 26% | $7,159 |
| 2013 | 74 | None | 0% (0) | 32% | $4,932 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 28 drugs
| Trulicity | 46 | $63,644 | $1,384 |
| Jardiance | 11 | $20,057 | $1,823 |
| Januvia | 15 | $14,735 | $982 |
| Atorvastatin | 68 | $1,803 | $27 |
| Diclofenac | 41 | $1,679 | $41 |
| Gabapentin | 48 | $1,673 | $35 |
| Omeprazole | 43 | $1,269 | $30 |
| Albuterol Sulfate Hfa | 16 | $1,058 | $66 |
| Tamsulosin | 19 | $937 | $49 |
| Metformin | 36 | $849 | $24 |
| Metoprolol | 14 | $670 | $48 |
| Fluticasone Propionate | 41 | $665 | $16 |
| Trazodone | 24 | $637 | $27 |
| Amlodipine Besylate | 28 | $598 | $21 |
| Oxycodone-Acetaminophen | 13 | $580 | $45 |
| Chlorthalidone | 16 | $550 | $34 |
| Losartan | 38 | $538 | $14 |
| Lisinopril | 36 | $496 | $14 |
| Levothyroxine | 15 | $430 | $29 |
| Glipizide | 12 | $382 | $32 |
| Alendronate | 16 | $370 | $23 |
| Allopurinol | 11 | $336 | $31 |
| Hydroxyzine | 17 | $290 | $17 |
| Hydrocodone-Acetaminophen | 14 | $220 | $16 |
| Famotidine | 12 | $190 | $16 |
| Furosemide | 14 | $137 | $10 |
| Simvastatin | 19 | $98 | $5 |
| Hydrochlorothiazide | 31 | $68 | $2 |
2022: 27 drugs
| Trulicity | 41 | $53,398 | $1,302 |
| Lantus | 13 | $5,436 | $418 |
| Gabapentin | 52 | $2,019 | $39 |
| Atorvastatin | 70 | $1,464 | $21 |
| Albuterol Sulfate Hfa | 23 | $1,144 | $50 |
| Metformin | 42 | $967 | $23 |
| Omeprazole | 44 | $937 | $21 |
| Lidocaine | 14 | $928 | $66 |
| Losartan | 35 | $689 | $20 |
| Glipizide | 17 | $649 | $38 |
| Fluticasone Propionate | 38 | $563 | $15 |
| Amlodipine Besylate | 21 | $528 | $25 |
| Diclofenac | 25 | $486 | $19 |
| Lisinopril | 40 | $476 | $12 |
| Chlorthalidone | 18 | $447 | $25 |
| Hydrocodone-Acetaminophen | 22 | $414 | $19 |
| Trazodone | 14 | $347 | $25 |
| Levothyroxine | 12 | $322 | $27 |
| Tamsulosin | 13 | $297 | $23 |
| Lisinopril-Hydrochlorothiazide | 12 | $282 | $24 |
| Hydroxyzine | 17 | $220 | $13 |
| Simvastatin | 23 | $200 | $9 |
| Ibuprofen | 11 | $189 | $17 |
| Furosemide | 17 | $171 | $10 |
| Metoprolol | 13 | $161 | $12 |
| Hydrochlorothiazide | 26 | $136 | $5 |
| Alendronate | 14 | $94 | $7 |
2021: 28 drugs
| Trulicity | 19 | $28,635 | $1,507 |
| Gabapentin | 56 | $1,791 | $32 |
| Albuterol Sulfate Hfa | 32 | $1,754 | $55 |
| Atorvastatin | 62 | $1,321 | $21 |
| Omeprazole | 67 | $975 | $15 |
| Fluticasone Propionate | 37 | $895 | $24 |
| Diclofenac | 37 | $881 | $24 |
| Metformin | 36 | $812 | $23 |
| Losartan | 38 | $722 | $19 |
| Oxycodone-Acetaminophen | 11 | $671 | $61 |
| Hydrocodone-Acetaminophen | 24 | $648 | $27 |
| Glipizide | 16 | $627 | $39 |
| Trazodone | 20 | $502 | $25 |
| Amlodipine Besylate | 31 | $468 | $15 |
| Tamsulosin | 16 | $464 | $29 |
| Simvastatin | 25 | $463 | $19 |
| Levothyroxine | 15 | $452 | $30 |
| Lisinopril | 54 | $404 | $7 |
| Lidocaine | 16 | $359 | $22 |
| Lisinopril-Hydrochlorothiazide | 20 | $325 | $16 |
| Chlorthalidone | 13 | $276 | $21 |
| Furosemide | 24 | $186 | $8 |
| Ibuprofen | 15 | $173 | $12 |
| Alendronate | 17 | $117 | $7 |
| Carvedilol | 12 | $103 | $9 |
| Metoprolol | 11 | $97 | $9 |
| Hydroxyzine | 11 | $93 | $8 |
| Hydrochlorothiazide | 28 | $90 | $3 |
2020: 30 drugs
| Trulicity | 17 | $20,820 | $1,225 |
| Novolog Flexpen | 12 | $6,650 | $554 |
| Basaglar Kwikpen U-100 | 14 | $6,166 | $440 |
| Comfort Ez Insulin | 11 | $1,502 | $137 |
| Comfort Ez Pen Needle | 11 | $1,112 | $101 |
| Gabapentin | 32 | $814 | $25 |
| Oxycodone-Acetaminophen | 12 | $703 | $59 |
| Albuterol Sulfate Hfa | 12 | $590 | $49 |
| Losartan | 30 | $544 | $18 |
| Glipizide | 20 | $529 | $26 |
| Lisinopril | 51 | $456 | $9 |
| Metformin | 24 | $455 | $19 |
| Atorvastatin | 37 | $451 | $12 |
| Levothyroxine | 17 | $421 | $25 |
| Omeprazole | 38 | $412 | $11 |
| Fluticasone Propionate | 15 | $390 | $26 |
| Simvastatin | 23 | $372 | $16 |
| Hydrocodone-Acetaminophen | 11 | $314 | $29 |
| Ibuprofen | 25 | $312 | $12 |
| Chlorthalidone | 14 | $297 | $21 |
| Ketoconazole | 11 | $270 | $25 |
| Trazodone | 19 | $258 | $14 |
| Lidocaine | 11 | $249 | $23 |
| Lisinopril-Hydrochlorothiazide | 16 | $204 | $13 |
| Amlodipine Besylate | 25 | $169 | $7 |
| Tamsulosin | 16 | $161 | $10 |
| Hydrochlorothiazide | 23 | $144 | $6 |
| Fluoxetine | 12 | $140 | $12 |
| Metoprolol | 13 | $131 | $10 |
| Furosemide | 11 | $75 | $7 |
2019: 21 drugs
| Trulicity | 13 | $16,864 | $1,297 |
| Novolog Flexpen | 12 | $6,686 | $557 |
| Proair Hfa | 19 | $1,609 | $85 |
| Gabapentin | 44 | $1,049 | $24 |
| Lidocaine | 27 | $668 | $25 |
| Oxycodone-Acetaminophen | 12 | $609 | $51 |
| Lisinopril | 49 | $501 | $10 |
| Chlorthalidone | 14 | $474 | $34 |
| Tamsulosin | 19 | $459 | $24 |
| Atorvastatin | 34 | $389 | $11 |
| Metformin | 28 | $384 | $14 |
| Glipizide | 26 | $361 | $14 |
| Simvastatin | 24 | $359 | $15 |
| Trazodone | 15 | $300 | $20 |
| Losartan | 25 | $299 | $12 |
| Omeprazole | 29 | $208 | $7 |
| Fluticasone Propionate | 13 | $155 | $12 |
| Amlodipine Besylate | 23 | $143 | $6 |
| Metoprolol | 11 | $127 | $12 |
| Ibuprofen | 16 | $107 | $7 |
| Hydrochlorothiazide | 20 | $74 | $4 |
2018: 22 drugs
| Tradjenta | 12 | $4,427 | $369 |
| Lidocaine | 30 | $1,471 | $49 |
| Proair Hfa | 25 | $1,459 | $58 |
| Simvastatin | 30 | $904 | $30 |
| Oxycodone-Acetaminophen | 12 | $596 | $50 |
| Lisinopril | 47 | $537 | $11 |
| Tamsulosin | 14 | $527 | $38 |
| Metformin | 27 | $476 | $18 |
| Chlorthalidone | 12 | $437 | $36 |
| Losartan | 28 | $412 | $15 |
| Glipizide | 28 | $329 | $12 |
| Atorvastatin | 27 | $321 | $12 |
| Fluticasone Propionate | 23 | $288 | $13 |
| Gabapentin | 20 | $265 | $13 |
| Levothyroxine | 11 | $243 | $22 |
| Metoprolol | 11 | $239 | $22 |
| Omeprazole | 18 | $191 | $11 |
| Amlodipine Besylate | 23 | $143 | $6 |
| Furosemide | 19 | $139 | $7 |
| Trazodone | 15 | $108 | $7 |
| Naproxen | 15 | $99 | $7 |
| Hydrochlorothiazide | 16 | $40 | $2 |
2017: 19 drugs
| Lidocaine | 17 | $1,176 | $69 |
| Proair Hfa | 17 | $976 | $57 |
| Gabapentin | 18 | $479 | $27 |
| Oxycodone-Acetaminophen | 11 | $478 | $43 |
| Atorvastatin | 27 | $455 | $17 |
| Tamsulosin | 13 | $444 | $34 |
| Chlorthalidone | 12 | $432 | $36 |
| Omeprazole | 31 | $417 | $13 |
| Simvastatin | 30 | $402 | $13 |
| Metoprolol | 12 | $368 | $31 |
| Amlodipine Besylate | 34 | $340 | $10 |
| Losartan | 20 | $288 | $14 |
| Lisinopril | 37 | $240 | $6 |
| Metformin | 21 | $210 | $10 |
| Fluticasone Propionate | 13 | $149 | $11 |
| Glipizide | 15 | $93 | $6 |
| Trazodone | 14 | $91 | $7 |
| Naproxen | 11 | $57 | $5 |
| Hydrochlorothiazide | 11 | $53 | $5 |
2016: 17 drugs
| Atrovent Hfa | 14 | $4,395 | $314 |
| Qvar | 18 | $3,442 | $191 |
| Proair Hfa | 17 | $1,203 | $71 |
| Tamsulosin | 12 | $928 | $77 |
| Pravastatin | 15 | $876 | $58 |
| Oxycodone-Acetaminophen | 11 | $771 | $70 |
| Levetiracetam | 12 | $614 | $51 |
| Atorvastatin | 18 | $352 | $20 |
| Omeprazole | 17 | $341 | $20 |
| Fluticasone Propionate | 18 | $290 | $16 |
| Losartan | 21 | $286 | $14 |
| Lisinopril | 29 | $243 | $8 |
| Simvastatin | 20 | $178 | $9 |
| Metformin | 21 | $177 | $8 |
| Amlodipine Besylate | 24 | $145 | $6 |
| Ibuprofen | 14 | $113 | $8 |
| Trazodone | 11 | $48 | $4 |
2015: 16 drugs
| Atrovent Hfa | 13 | $3,568 | $274 |
| Qvar | 13 | $2,341 | $180 |
| Oxycodone-Acetaminophen | 11 | $2,066 | $188 |
| Proair Hfa | 17 | $1,505 | $89 |
| Tamsulosin | 11 | $802 | $73 |
| Pravastatin | 14 | $734 | $52 |
| Hydrocodone-Acetaminophen | 14 | $691 | $49 |
| Fluticasone Propionate | 23 | $431 | $19 |
| Atorvastatin | 11 | $354 | $32 |
| Losartan | 19 | $292 | $15 |
| Lisinopril | 30 | $286 | $10 |
| Omeprazole | 11 | $208 | $19 |
| Simvastatin | 20 | $168 | $8 |
| Amlodipine Besylate | 20 | $158 | $8 |
| Metformin | 17 | $100 | $6 |
| Hydrochlorothiazide | 19 | $80 | $4 |
2014: 3 drugs
| Atrovent Hfa | 13 | $3,275 | $252 |
| Levetiracetam | 12 | $434 | $36 |
| Simvastatin | 11 | $148 | $13 |
2013: 1 drug
| Levetiracetam | 19 | $698 | $37 |
Professional record
- NPI
- 1265631709
- Licence
- CA A115912California A115912: Current · expires 2026-11-30
More record details
- Sole proprietor
- No
- Taxonomy
- Family medicine (207Q00000X)
- Mailing address
- 5530 Ne 42nd Ave, Portland, OR, 97218
- NPI first listed
- 2007-07-14
- NPI last updated
- 2026-04-13
- NPI record certified
- 2026-04-13
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1885 Bay Rd, East Palo Alto, CA, 94303 · 1265 Welch Rd Fl 3, Stanford, CA, 94305 · 300 Pasteur Dr, Stanford, CA, 94305